AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24961378 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving assessment only
Number of subjects: 0
Study 24351556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa roxburghii tratt preparation (120 ml/d for one month)
Number of subjects: 62
Study 24351556 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD-enriched rosa roxburghii tratt juice (120 ml/d for one month)
Number of subjects: 62
Study 24351556 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy residents)
Number of subjects: 62
Study 24351556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa roxburghii tratt preparation
Number of subjects: 62
Study 24351556 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD-enriched rosa roxburghii tratt juice
Number of subjects: 62
Study 20672729 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioflow (Ivoclar Vivadent)
Number of subjects: 30
Study 20672729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Flow
Number of subjects: 30
Study 20672729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 30
Study 20672729 — intervention group
Group type: EXPERIMENTAL
Intervention: experimental flowable composite
Number of subjects: 30
Study 20672729 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliomolar HB (Ivoclar Vivadent)
Number of subjects: 30
Study 20672729 — intervention group
Group type: COMPARATOR
Intervention: No base
Number of subjects: 30
Study 19166420 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LFT group)
Number of subjects: 463
Study 19166420 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LFT group)
Number of subjects: 463
Study 19166420 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LPZ group)
Number of subjects: 463
Study 19166420 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LPZ group)
Number of subjects: 463
Study 16624682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 776
Study 16624682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mitral regurgitation
Number of subjects: 776
Study 16624682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma brain natriuretic peptide (BNP) levels
Number of subjects: 776
Study 16624682 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 776
Study 11978752 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with CLD
Number of subjects: 43
Study 11978752 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with RDS
Number of subjects: 43
Study 11978752 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 43
Study 11978752 — intervention group
Group type: EXPERIMENTAL
Intervention: RDS and CLD groups
Number of subjects: 43
Study 9925196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated cups (group B)
Number of subjects: 185
Study 9925196 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium coated cups (group C)
Number of subjects: 185
Study 9925196 — intervention group
Group type: COMPARATOR
Intervention: Uncoated cups (group A)
Number of subjects: 185
Study 9925196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite and titanium coated cups (groups B and C)
Number of subjects: 185
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prestimulus at 0.1 s and 1 s ISI in the warned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prestimulus at 0.1 s ISI in the unwarned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prestimulus at 0.1 s ISI in the warned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prestimulus at all three intervals in the warned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic prestimulus at 0.1 s and 1 s ISI in the warned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic prestimulus at 0.1 s ISI in the unwarned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and acoustic prestimuli at 0.1 s ISI in the warned group
Number of subjects: 20
Study 8788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and acoustic prestimuli at 0.1 s ISI in the unwarned group
Number of subjects: 20
Study 2319784 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique (group I)
Number of subjects: 63
Study 2319784 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique (group II)
Number of subjects: 63
Study 7437583 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad band noise
Number of subjects: 0
Study 7437583 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 Hz pure tone
Number of subjects: 0
Study 7437583 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 Hz pure tone
Number of subjects: 0
Study 7437583 — intervention group
Group type: COMPARATOR
Intervention: No-sound controls
Number of subjects: 0
Study 31119383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (IA-TXA)
Number of subjects: 228
Study 31119383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (IV-TXA)
Number of subjects: 228
Study 31119383 — intervention group
Group type: COMPARATOR
Intervention: No-TXA
Number of subjects: 228
Study 31119383 — intervention group
Group type: COMPARATOR
Intervention: Open-box TKA
Number of subjects: 228
Study 31119383 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-box TKA
Number of subjects: 228
Study 27048705 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing Talk (CHAT) communication training
Number of subjects: 42
Study 25957542 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (180 mg capsules once daily for 12 weeks)
Number of subjects: 60
Study 25957542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 60
Study 23333782 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated electronic alerts
Number of subjects: 0
Study 23333782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 0
Study 23333782 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up (after alerts ceased)
Number of subjects: 0
Study 21392474 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 48
Study 21392474 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 48
Study 18486308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 47
Study 18486308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17709252 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic organ bath
Number of subjects: 80
Study 17709252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical verapamil-nitroglycerin solution
Number of subjects: 80
Study 17709252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of normothermic organ bath and verapamil-nitroglycerin solution
Number of subjects: 80
Study 17709252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antispasmodic treatment)
Number of subjects: 80
Study 14717629 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective self-verification with high certainty
Number of subjects: 0
Study 14717629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ties to source of self-verification
Number of subjects: 0
Study 14717629 — intervention group
Group type: EXPERIMENTAL
Intervention: Salience of collective self
Number of subjects: 0
Study 14717629 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of group identification
Number of subjects: 0
Study 11678970 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated Type 2 diabetes
Number of subjects: 38
Study 11678970 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 38
Study 9298430 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 543
Study 9298430 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 543
Study 8485065 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol (0.2 mg/kg)
Number of subjects: 12
Study 8485065 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (6-mercaptopurine 70 mg/m2 days 1-14, methotrexate 15 mg/m2 twice weekly days 15-28, reinduction with daunorubicin 35 mg/m2 and vincristine 1 mg/m2 day 29)
Number of subjects: 295
Study 3524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus stanozolol (0.15 mg/kg/day)
Number of subjects: 295
Study 3524789 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine (70 mg/m2 orally on 4 consecutive days) and cytosine arabinoside (80 mg/m2 subcutaneously day 5 every week)
Number of subjects: 295
Study 3524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus irradiated blast cells treated with neuraminidase
Number of subjects: 295
Study 3524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 295
Study 3524789 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 295
Study 31865906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 41
Study 31865906 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise
Number of subjects: 41
Study 31865906 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MBSR and structured exercise
Number of subjects: 41
Study 28687420 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 326
Study 28687420 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 326
Study 25970439 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-rich dairy based meal (1352 ± 53 mg calcium)
Number of subjects: 32
Study 25970439 — intervention group
Group type: COMPARATOR
Intervention: Control meal (46 ± 7 mg calcium)
Number of subjects: 32
Study 23123039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% at 2 cc/h)
Number of subjects: 67
Study 23123039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5% saline at 2 cc/h)
Number of subjects: 67
Study 21721397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, home-based pulmonary rehabilitation
Number of subjects: 32
Study 21721397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 19002073 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth Jump (DJ) training for 6 weeks, twice weekly
Number of subjects: 12
Study 19002073 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ) training for 6 weeks, twice weekly
Number of subjects: 12
Study 16481803 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 3 mg.kg‐1 (group 1)
Number of subjects: 100
Study 16481803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg‐1 (group 3)
Number of subjects: 100
Study 16481803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine aerosol 10% to oropharyngolaryngeal structures topically (group 4)
Number of subjects: 100
Study 16481803 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline physiologic 5 mL (group 2)
Number of subjects: 100
Study 15061262 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar bone scintigraphy using 99mTc methylene diphosphonate
Number of subjects: 28
Study 15061262 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT bone scintigraphy
Number of subjects: 28
Study 15061262 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar scans
Number of subjects: 28
Study 15061262 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT scans
Number of subjects: 28
Study 15061262 — intervention group
Group type: COMPARATOR
Intervention: X-ray results
Number of subjects: 28
Study 15061262 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT results
Number of subjects: 28
Study 10869301 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy plus interferon
Number of subjects: 96
Study 10869301 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy alone
Number of subjects: 96
Study 10869301 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 96
Study 9542000 — intervention group
Group type: EXPERIMENTAL
Intervention: Topinambur concentrate
Number of subjects: 0
Study 8239044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 15
Study 3519093 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid plus oxethazaine (8 ml doses as needed for 4 weeks)
Number of subjects: 40
Study 3519093 — intervention group
Group type: COMPARATOR
Intervention: Antacid alone (8 ml doses as needed for 4 weeks)
Number of subjects: 40
Study 3661486 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 8
Study 3661486 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymers
Number of subjects: 8
Study 31759034 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Number of subjects: 22
Study 31590285 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO) 40g/d
Number of subjects: 64
Study 31590285 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (SUC) 40g/d
Number of subjects: 64
Study 31590285 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO)
Number of subjects: 64
Study 31590285 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast containing Isomaltulose (ISO)
Number of subjects: 64
Study 27522164 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and Prednisone with Lenalidomide
Number of subjects: 208
Study 27522164 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and Prednisone with Placebo
Number of subjects: 208
Study 26244520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 400 µg
Number of subjects: 1167
Study 26244520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 1167
Study 26244520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1167
Study 26244520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 400 µg and Nifedipine 30 mg
Number of subjects: 1167
Study 24122181 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinacrine (300 mg daily)
Number of subjects: 51
Study 24122181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 22008301 — intervention group
Group type: EXPERIMENTAL
Intervention: HG plus maxillary acrylic biteplate (BP)
Number of subjects: 131
Study 22008301 — intervention group
Group type: COMPARATOR
Intervention: Headgear (HG)
Number of subjects: 131
Study 17824846 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (continuous positive airway pressure) treatment; duration: 1 month; n=12
Number of subjects: 19
Study 17824846 — intervention group
Group type: COMPARATOR
Intervention: Control group; n=7
Number of subjects: 19
Study 16837619 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day for 3 months (Group S2)
Number of subjects: 88
Study 16837619 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day for 3 months (Group S22)
Number of subjects: 88
Study 16837619 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day (Group S212)
Number of subjects: 88
Study 16837619 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg L-selenomethionine per day (Group S21)
Number of subjects: 88
Study 16837619 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day (Group S2)
Number of subjects: 88
Study 16837619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 88
Study 16837619 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day (Group S222)
Number of subjects: 88
Study 12570285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-up training group
Number of subjects: 102
Study 12570285 — intervention group
Group type: EXPERIMENTAL
Intervention: Curl-up training group
Number of subjects: 102
Study 12570285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 11482709 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography of diastolic transmitral flow velocities
Number of subjects: 24
Study 11482709 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine infusion at 10 mcg/kg/min
Number of subjects: 24
Study 9575668 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (116 subjects with subjective symptoms)
Number of subjects: 188
Study 9575668 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (72 subjects without subjective or objective symptoms)
Number of subjects: 188
Study 9575668 — intervention group
Group type: COMPARATOR
Intervention: Control group (194 persons with normal EEG)
Number of subjects: 188
Study 8097082 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine (2.25 mg/d)
Number of subjects: 111
Study 8097082 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (500 to 1200 mg/d)
Number of subjects: 111
Study 3709638 — intervention group
Group type: EXPERIMENTAL
Intervention: cadralazine 15 mg once daily
Number of subjects: 20
Study 3709638 — intervention group
Group type: COMPARATOR
Intervention: chlorthalidone 25 mg once daily
Number of subjects: 20
Study 31699944 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV therapy using fixed-dose combination (tenofovir, lamivudine, efavirenz)
Number of subjects: 75
Study 28124288 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (I-CBT)
Number of subjects: 174
Study 28124288 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring, feedback, and support (I-MFS)
Number of subjects: 174
Study 28124288 — intervention group
Group type: COMPARATOR
Intervention: Both I-CBT and I-MFS
Number of subjects: 174
Study 26613606 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant/palonosetron 300/0.5 mg
Number of subjects: 0
Study 26613606 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 0.5 mg
Number of subjects: 0
Study 23799210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate and magnesium citrate
Number of subjects: 181
Study 23799210 — intervention group
Group type: COMPARATOR
Intervention: 4-liter split-dose polyethylene glycol (PEG)
Number of subjects: 181
Study 22749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulation
Number of subjects: 141
Study 22749961 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 141
Study 19772446 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin
Number of subjects: 411
Study 19772446 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 411
Study 17537207 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping and ablation for right AMRT
Number of subjects: 33
Study 17537207 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping and ablation for left AMRT
Number of subjects: 33
Study 15350182 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 125
Study 15350182 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 125
Study 15350182 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA
Number of subjects: 125
Study 15350182 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 120 mg
Number of subjects: 125
Study 11952434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 0
Study 11952434 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 9481634 — intervention group
Group type: COMPARATOR
Intervention: Formula (F)
Number of subjects: 14
Study 9481634 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula mixed with rice cereal (F + R)
Number of subjects: 14
Study 8591079 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM2 chemotherapy
Number of subjects: 314
Study 8591079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FAM2 chemotherapy)
Number of subjects: 314
Study 2121487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (streptokinase, t‐PA, APSAC)
Number of subjects: 0
Study 90217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice a day
Number of subjects: 0
Study 90217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31784747 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 170
Study 31784747 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 170
Study 31164489 — intervention group
Group type: EXPERIMENTAL
Intervention: IQOS packaging designs (three designs with varying links to Marlboro brand)
Number of subjects: 954
Study 28831539 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for diabetes and cardiovascular risk assessment
Number of subjects: 139075
Study 28831539 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 139075
Study 25995276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) delivered biweekly to homes
Number of subjects: 1612
Study 25995276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs)
Number of subjects: 1612
Study 22998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB‐FFP)
Number of subjects: 293
Study 22998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent (S/D‐FFP)
Number of subjects: 293
Study 22998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarantine (Q‐FFP)
Number of subjects: 293